• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TWST

    Twist Bioscience Corporation

    Subscribe to $TWST
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: twistbioscience.com

    Peers

    $ILMN

    Recent Analyst Ratings for Twist Bioscience Corporation

    DatePrice TargetRatingAnalyst
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    2/7/2022$130.00 → $75.00Overweight
    Barclays
    2/7/2022$110.00 → $70.00Market Perform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    See more ratings

    Twist Bioscience Corporation SEC Filings

    See more
    • SEC Form 10-Q filed by Twist Bioscience Corporation

      10-Q - Twist Bioscience Corp (0001581280) (Filer)

      5/5/25 4:05:23 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Twist Bioscience Corp (0001581280) (Filer)

      5/5/25 7:27:31 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

      SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      4/17/25 9:35:32 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Twist Bioscience Corporation

      144 - Twist Bioscience Corp (0001581280) (Subject)

      2/21/25 3:13:04 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Twist Bioscience Corporation

      S-8 - Twist Bioscience Corp (0001581280) (Filer)

      2/12/25 4:37:31 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

      SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      2/12/25 4:35:31 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Twist Bioscience Corp (0001581280) (Filer)

      2/11/25 5:00:21 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Twist Bioscience Corporation

      SCHEDULE 13G - Twist Bioscience Corp (0001581280) (Subject)

      2/5/25 7:48:59 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Twist Bioscience Corporation

      10-Q - Twist Bioscience Corp (0001581280) (Filer)

      2/3/25 4:09:45 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Twist Bioscience Corp (0001581280) (Filer)

      2/3/25 7:18:16 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Financials

    Live finance-specific insights

    See more
    • Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f

      5/5/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Spins Out DNA Data Storage as Independent Company

      Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev

      5/5/25 7:10:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor

      4/14/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss it

      2/3/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the

      1/22/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2024 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. E

      11/18/24 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to

      10/24/24 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results

      – Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 – — Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at approximately 42.0% — — Company to host conference call today at 8:00 a.m. Eastern Time — Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2024 ended June 30, 2024. "We

      8/2/24 7:30:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday, August 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference

      7/11/24 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

      – Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 – – Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 – — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% — — Company to host conference call today at 4:30 p.m. Eastern Time — Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024. "This was another very strong quarter for Twi

      5/2/24 4:05:00 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Twist Bioscience and Ginkgo Bioworks Revise Collaboration

      New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15

      5/8/25 8:00:00 AM ET
      $DNA
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f

      5/5/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Spins Out DNA Data Storage as Independent Company

      Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev

      5/5/25 7:10:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

      Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets now includes industry leading number of unique indexes at 3,072 HT UDI Adapters Enables multiplexing and high throughput sequencing Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the expanded launch of the Twist High Throughput (HT) Unique Dual Index (UDI) Adapter System to enable multiplexing and sample batching at scale. Indexing is a critical part of the li

      4/24/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor

      4/14/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

      Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations Companies to present poster at AGBT-Ag Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist's FlexPrep™ Ultra-High Throughput (UHT) Library Preparation Kit with Curio's bioinformatics software and data platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/

      3/31/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

      — Supports Acceleration of Research Across Multiple Industries; Maximizes Budget — Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. "At Twist, we recognize the increasing challenge within colleges, universities and research institutions to securing research funding and appreciate that scientific progress must continue unhindered, as Science Doesn't Stop," said Emily M. Leproust, Ph.D.,

      3/11/25 7:30:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Present at Upcoming Investor Conferences

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 in Boston, MA; fireside chat at 1:50 pm Eastern Time Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the Leerink Global Biopharma Conference 2025 on Tuesday, March 11 in Miami, FL; fireside chat at 9:

      2/25/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 123,024 equity awards, consisting of 72,394 restricted stock units ("RSUs") and up to 50,630 performance stock units ("PSUs"), to 32 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in acco

      2/19/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss it

      2/3/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Cho Dennis sold $163,590 worth of shares (5,000 units at $32.72), decreasing direct ownership by 5% to 105,849 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/9/25 4:05:06 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and COO Finn Patrick John sold $105,423 worth of shares (2,800 units at $37.65), decreasing direct ownership by 1% to 262,660 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:18 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Cho Dennis sold $25,942 worth of shares (689 units at $37.65), decreasing direct ownership by 0.62% to 110,849 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:21 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Leproust Emily M. sold $189,836 worth of shares (5,042 units at $37.65), decreasing direct ownership by 0.76% to 655,432 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:12 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP of Human Resources Green Paula sold $41,454 worth of shares (1,101 units at $37.65), decreasing direct ownership by 0.84% to 129,380 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:16 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Werner Robert F. sold $6,099 worth of shares (162 units at $37.65), decreasing direct ownership by 0.31% to 51,272 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:16 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and COO Finn Patrick John sold $82,310 worth of shares (2,058 units at $39.99), decreasing direct ownership by 0.77% to 265,460 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      4/25/25 4:05:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and COO Finn Patrick John sold $7,979 worth of shares (206 units at $38.73), decreasing direct ownership by 0.08% to 267,518 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      4/4/25 4:05:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Cho Dennis sold $4,803 worth of shares (124 units at $38.73), decreasing direct ownership by 0.11% to 111,538 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      4/4/25 4:05:10 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP of Human Resources Green Paula sold $5,423 worth of shares (140 units at $38.73), decreasing direct ownership by 0.11% to 130,481 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      4/4/25 4:05:06 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      11/8/24 2:38:08 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Twist Bioscience Corporation

      SC 13G - Twist Bioscience Corp (0001581280) (Subject)

      11/8/24 9:39:34 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      11/5/24 6:07:26 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      8/9/24 1:40:34 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      7/9/24 6:04:26 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Twist Bioscience Corporation (Amendment)

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      2/12/24 5:55:02 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Twist Bioscience Corporation

      SC 13G - Twist Bioscience Corp (0001581280) (Subject)

      2/12/24 5:42:54 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Twist Bioscience Corporation

      SC 13G - Twist Bioscience Corp (0001581280) (Subject)

      2/12/24 6:07:26 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Twist Bioscience Corporation (Amendment)

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      2/9/24 10:05:20 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Twist Bioscience Corporation (Amendment)

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      2/5/24 6:08:57 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

      For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

      3/26/21 3:51:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Leadership Updates

    Live Leadership Updates

    See more

    Twist Bioscience Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

      10/15/24 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

      1/5/24 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations. Mr. Buck brings experience improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. "Building on the foundation of his time serving in the United State Marine Corps and drawing from military efficiency, Mark has established a career in industry developing and optimizing operational processes and requirements that enable scale for multiple

      10/3/23 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Chet Gandhi as Chief Information Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings a wealth of experience in leading and executing software and information technology strategies to enable the growth of global public and private companies. "With a strong track record of success, Chet's expertise will play a crucial role in driving automation and supporting Twist's expansion efforts as we strive to grow our customer base from over three thousand to over one hundred thousand," said Emily M. Leproust, Ph.D., CEO and co-f

      6/20/23 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Robert Werner as Chief Accounting Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. "Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in revenue," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "He will be an invaluable addition as Twist continues to gain market share and execute against our plan to achieve adjusted EBITDA breakeven for the core and biopharma businesses at the close of the fiscal fourth quarter of 2024." "I have spent the

      5/23/23 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

      BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

      5/11/22 8:01:00 AM ET
      $NKTR
      $TWST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Steffen Hellmold to the newly created position of senior vice president, business development, data storage. "We have made significant technological advances in our DNA data storage division and are now focused on laying the foundation for commercialization of this disruptive and important storage solution. The addition of Steffen to the team will help to define our commercialization strategy and build important relationships as we move towards more accessible DNA data storage solutions," commen

      10/12/21 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Dennis Cho as senior vice president, general counsel and chief ethics and compliance officer. Mr. Cho brings more than 25 years of corporate legal experience, most of which has been in the biotech industry. "Dennis is a giant of biopharma deals with a proven track record in, and commitment to, the biotech industry. He has provided counsel on all types of transactions and collaborations, which makes him ideal for the role at Twist," commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist

      9/27/21 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it appointed Melissa Starovasnik, Ph.D. to its board of directors. Dr. Starovasnik most recently served as Senior Scientific Advisor, Research at Genentech, Inc. and brings nearly three decades of experience in protein and antibody drug discovery and development. "Melissa's extensive leadership and scientific experience will be valuable to Twist as we leverage our DNA platform to support our broad base of customers across the synthetic biology and biopharmaceutical industries," said Emily M. Leproust, Ph.D., CEO a

      8/6/21 7:30:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wolfe Research initiated coverage on Twist Bioscience with a new price target

      Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

      12/13/24 8:32:53 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Twist Bioscience with a new price target

      Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

      6/4/24 7:44:10 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience upgraded by Goldman with a new price target

      Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously

      1/17/24 7:47:50 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Berenberg initiated coverage on Twist Bioscience with a new price target

      Berenberg initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $27.00

      9/27/23 7:26:21 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Twist Bioscience with a new price target

      Scotiabank initiated coverage of Twist Bioscience with a rating of Sector Outperform and set a new price target of $33.00

      1/5/23 7:28:04 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Twist Bioscience from In-line to Outperform and set a new price target of $36.00 from $28.00 previously

      1/3/23 7:43:40 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cowen resumed coverage on Twist Bioscience

      Cowen resumed coverage of Twist Bioscience with a rating of Outperform

      3/2/22 8:43:12 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on Twist Bioscience with a new price target

      Barclays reiterated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $75.00 from $130.00 previously

      2/7/22 6:53:52 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Twist Bioscience with a new price target

      SVB Leerink reiterated coverage of Twist Bioscience with a rating of Market Perform and set a new price target of $70.00 from $110.00 previously

      2/7/22 4:30:02 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cowen resumed coverage on Twist Bioscience

      Cowen resumed coverage of Twist Bioscience with a rating of Outperform

      10/15/21 7:32:34 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care